Clinical studies of Batroxobin in the treatment of acute evolving cerebral infarction

Objective To study the efficacy and safety of Batroxobin in the treatment of acute evolving cerebral infarction. Methods Fifty five cases of acute evolving cerebral infarction were randomly divided into treatment group and control group. The patients in each group were treated with Dextran as the basic management. Batro xobin was added to the treatment group, with the first dose of 10 BU,then,5 BU was given every other day until a total dose of 25 BU. Ligustrazini Hydrochloridum was added to the control group. Results The end of progression of infarction in the treatment group were significantly earlier than that in the control group. From 3 days onward, the neuro function deficit score(NFD) in the treatment group was better than that in the control group( P =0.044), and this difference was increased ( P =0.000)at 14 days. The serum fibrinogen level was decreased significantly in the treatment group. Conclusion Batroxobin can provide favourable effect for ending off the progression for patients with acute evolving cerebral infarction and promote the recovery of the neurofunction of the patient.